Larimar Therapeutics to Participate in the Guggenheim Virtual Neuro/Immunology Conference

BALA CYNWYD, Pa., Nov. 15, 2021 (GLOBE NEWSWIRE) -- Larimar Therapeutics, Inc. (“Larimar”) (Nasdaq: LRMR), a clinical-stage biotechnology company focused on developing treatments for complex rare diseases, today announced that company management will participate in 1x1 investor meetings at the Guggenheim Virtual Neuro/Immunology Conference taking place November 15 – 16, 2021.

About Larimar TherapeuticsLarimar Therapeutics, Inc. (Nasdaq: LRMR), is a clinical-stage biotechnology company focused on developing treatments for complex rare diseases. Larimar’s lead compound, CTI-1601, is currently being evaluated in a Phase 1 clinical program in the U.S. as a potential treatment for Friedreich's ataxia. Larimar also plans to use its intracellular delivery platform to design other fusion proteins to target additional rare diseases characterized by deficiencies in intracellular bioactive compounds. For more information, please visit: https://larimartx.com.

Investor Contact:Joyce AllaireLifeSci Advisors[email protected] (212) 915-2569

Company Contact:Michael CelanoChief Financial Officer[email protected](484) 414-2715

You May Also Be Interested In

• CZR Alert: Monsey Firm of Wohl & Fruchter Renews Investigation of the Proposed Sale of Caesars Entertainment to Fertitta Entertainment  
• TRON H1 2026 Strategy Report: Anchored by DeFi, Driven by AI to Lead Crypto's Next Cycle
• Brewster Heights Orchard & Packing and Heritage Orchard Alliance Transaction Advances Following Agreement with Major Creditor